Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ribs

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Ribs. Displaying page 1 of 1.
    EudraCT Number: 2012-000123-41 Sponsor Protocol Number: B3D-EW-GHDW Start Date*: 2012-09-20
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Teriparatide and Risedronate in the Treatment of Patients with Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures
    Medical condition: Postmenopausal women with established osteoporosis and at least two moderate or one severe prevalent fragility fracture.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10031288 Osteoporosis with fracture LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) DE (Completed) AT (Completed) IT (Completed) HU (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001657-27 Sponsor Protocol Number: -- Start Date*: 2018-10-03
    Sponsor Name:
    Full Title: Comparison of ultrasound guided Serratus Anterior Plane Block (SAPB) with continuous local anesthetic infusion and epidural analgesia in the treatment of multiple rib fracture analgesia: a prospect...
    Medical condition: Multiple traumatic rib fractures
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001456-11 Sponsor Protocol Number: 20070337 Start Date*: 2012-04-17
    Sponsor Name:Amgen Inc
    Full Title: A Multicenter, International, Randomized, Double-blind, Placebo controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
    Medical condition: Postmenopausal Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BE (Completed) DK (Completed) PL (Completed) DE (Completed) GB (Completed) EE (Completed) CZ (Completed) ES (Completed) LV (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003142-41 Sponsor Protocol Number: 20110142 Start Date*: 2012-03-28
    Sponsor Name:AMGEN INC.
    Full Title: A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of AMG 785 in the Treatment of Postmenopausal Women With Osteoporosis
    Medical condition: Postmenopausal osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) LT (Completed) FI (Completed) PL (Completed) BE (Completed) CZ (Completed) ES (Completed) EE (Completed) GR (Completed) DE (Completed) GB (Completed) SE (Completed) AT (Completed) DK (Completed) LV (Completed) NO (Completed) NL (Completed) HU (Completed) IE (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-024177-39 Sponsor Protocol Number: RIBS-MIC/002/2010 Start Date*: 2011-02-01
    Sponsor Name:ALFA WASSERMANN
    Full Title: Prospective microbiological study on patients with non-constipation IBS treated with rifaximin 550 mg tablets.
    Medical condition: Non constipation Irritable Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060845 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003228-39 Sponsor Protocol Number: D4320C00033 Start Date*: 2008-02-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metasta...
    Medical condition: hormone-resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) NL (Completed) GB (Prematurely Ended) FR (Completed) CZ (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) PT (Prematurely Ended) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003227-20 Sponsor Protocol Number: ZD4054 Start Date*: 2007-09-27
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free...
    Medical condition: hormone-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10062904 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Prematurely Ended) DE (Completed) BE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) NL (Completed) FR (Completed) PT (Completed) DK (Prematurely Ended) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002751-28 Sponsor Protocol Number: PVO-2A-201 Start Date*: 2018-10-16
    Sponsor Name:Clementia Pharmaceuticals Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects with Multiple Osteochondromas
    Medical condition: Multiple Osteochondromas (MO)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10079019 Hereditary multiple osteochondromas PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Completed) PT (Prematurely Ended) FR (Completed) IT (Prematurely Ended) NL (Completed) BE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-000344-24 Sponsor Protocol Number: D4320C00006 Start Date*: 2004-10-29
    Sponsor Name:AstraZeneca AB
    Full Title: A phase II, randomised, double-blind, parallel-group, placebo-controlled, multi-centre study to assess the efficacy and safety of once-daily orally administered ZD4054 15 mg and 10 mg doses in pain...
    Medical condition: Hormone-refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10062904 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) SE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-003288-24 Sponsor Protocol Number: GRN163LMYF3001 Start Date*: 2021-05-10
    Sponsor Name:Geron Corporation
    Full Title: A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/...
    Medical condition: Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) BE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019856-30 Sponsor Protocol Number: CLDE225B2307 Start Date*: 2010-06-29
    Sponsor Name:NOVARTIS FARMA
    Full Title: A randomized, double-blind, vehicle-controlled, multicenter trial of topically administered LDE225 cream [0.75% bid] to evaluate clearance of Basal Cell Carcinoma in adult patients with Nevoid B...
    Medical condition: Basal Cell Carcinoma in adult patients with Nevoid Basal Cell Carcinoma Syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10004146 Basal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001516-30 Sponsor Protocol Number: GDX-44-007 Start Date*: Information not available in EudraCT
    Sponsor Name:GUERBET
    Full Title: Pharmacokinetics, safety and efficacy of a new gadolinium-based contrast agent, gadopiclenol, in pediatric patients from 2 to 17 years of ageundergoing contrast-enhanced MRI.
    Medical condition: Pediatric subjects from 2 to 17 years old scheduled to undergo routine gadolinium contrast enhanced Magnetic Resonance Imaging of Central Nervous System
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022891 - Investigations 10029817 Nuclear magnetic resonance imaging brain PT
    21.1 10022891 - Investigations 10072232 Nuclear magnetic resonance imaging spinal PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Ongoing) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2022-001358-41 Sponsor Protocol Number: VERCLBP002 Start Date*: 2023-02-27
    Sponsor Name:Vertanical GmbH
    Full Title: Multicentre, randomized, open-label study to prove an additional benefit of the full-spectrum cannabis extract VER-01 over opioids in the treatment of patients with chronic non-specific low back pain.
    Medical condition: Chronic non-specific low back pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Temporarily Halted) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004274-15 Sponsor Protocol Number: Pelle-926-201 Start Date*: 2016-02-22
    Sponsor Name:PellePharm, Inc.
    Full Title: Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndr...
    Medical condition: Basal Cell Nevus Syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10004151 Basal cell nevus syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001048-40 Sponsor Protocol Number: B1371013 Start Date*: 2015-02-10
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, 10017
    Full Title: A phase 2, double-blind, randomized safety and efficacy study of Glasdegib (PF-04449913) versus placebo in patients with Myelofibrosis previously treated with ruxolitinib.
    Medical condition: Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001436-10 Sponsor Protocol Number: INCB18424-266 Start Date*: 2015-02-26
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non–Small C...
    Medical condition: Nonsquamous NSCLC that is Stage IIIB, Stage IV, or recurrent
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DK (Prematurely Ended) ES (Prematurely Ended) NL (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000111-69 Sponsor Protocol Number: PAC303 Start Date*: 2020-08-04
    Sponsor Name:CTI BioPharma Corp.
    Full Title: PACIFICA Phase 3: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thro...
    Medical condition: Primary Myelofibrosis, Post-essential thrombocythemia myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL), Post polycythaemia vera myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074691 Post polycythaemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074692 Post essential thrombocythaemia myelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 13:06:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA